Anavex Life Sciences Corp (AVXL)

[nidan7500]

As a physician and researcher who investigates the efficacy of medicines, I have been watching this story unfold over the past year. As of right now, I am certain of one thing: With 6 million people in the United States suffering from Alzheimer’s, and current treatments only marginally effective, there is a desperate need for medications that can slow the disease.

But the evidence on Aduhelm so far is contradictory. Two Phase III clinical trials were stopped early after an independent committee, appointed by Biogen, analyzed the data and reported the studies were unlikely to show Aduhelm would demonstrate a benefit. This is not unusual; clinical trials are often stopped when early data suggests a drug will not work

https://theconversation.com/the-fda-approved-a-new-drug-to-treat-alzheimers-but-medicare-wont-always-pay-for-it-a-doctor-explains-what-researchers-know-about-biogens-aduhelm-179177

Note: considering the overall medical/financial priorities and importance of the issues around AD we might expect a supportive atmosphere w/FDA if A2-73 results warrant such.